<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011776</url>
  </required_header>
  <id_info>
    <org_study_id>FML-001</org_study_id>
    <secondary_id>FML-001</secondary_id>
    <nct_id>NCT02011776</nct_id>
  </id_info>
  <brief_title>A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome</brief_title>
  <official_title>A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santen Pharmaceutical(China) Co.,LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santen Pharmaceutical(China) Co.,LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of fluorometholone combined with
      sodium hyaluronate eye drops in the treatment of Sjögren syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Weeks</target_duration>
  <primary_outcome>
    <measure>tear—film breakup time</measure>
    <time_frame>the enrolling day,2 weeks after treatment,4 weeks after treatment,8 weeks after treatment</time_frame>
    <description>stain the cornea with the fluorescein; close the eye; open the eye and keep the eye open,count the seconds until the first black spot appears.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmer test I without anesthesia</measure>
    <time_frame>the enrolling day,2 weeks after treatment,4 weeks after treatment, 8 weeks after treatment</time_frame>
    <description>put the Schirmer test strip into the lower conjunctival sac; close the eye for 5 minutes; read the score of the test strip</description>
  </primary_outcome>
  <primary_outcome>
    <measure>corneal fluorescein staining</measure>
    <time_frame>the enrolling day,2 weeks after treatment,4 weeks after treatment,8 weeks after treatment</time_frame>
    <description>Fluorescein staining scores were measured on 0-3 point scale, in each quarter of corneal zone: 0(No staining), 1(some staining), 2(Staining in more than a half of the area), 3(Staining in the whole area).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Sjögren Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>using the 0.1% fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>using the 0.5% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        the people who suffered from the dry eye disease coused by the Sjögren syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  willing to participate in this clinical study, and signed informed consent

          -  age from 18 to 70 years old,both genders are permitted

          -  diagnosed as the Sjögren syndrome

          -  have the symptoms and signs of dry eye disease as below:

               1. have at least 2 symptoms such as dryness,foreign body sensation ,eye
                  strain,conjunctival congestion,secretion.The summed up score of symptoms greater
                  than 6.

               2. the score of tear-film break up time less than 5 seconds or the score of Schirmer
                  test less than 5mm/5min.

               3. the score of corneal fluorescein staining greater than 3.

                  Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eye &amp; ENT Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Santen Pharmaceutical(China) Co.,LTD</investigator_affiliation>
    <investigator_full_name>Lan Gong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Corticosteroids Dry Eye Sjögren syndrome inflammation treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

